Background: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disorder of unknown aetiology, which when left untreated can lead to liver cirrhosis and hepatic failure. Current treatment strategies include long-term treatment with corticosteroids and/or azathioprine. Most patients respond well to immunosuppressive therapy and treatment usually results in an asymptomatic course of AIH in remission. Nevertheless, both drugs are associated with serious side effects that can sometimes be severe and may necessitate drug withdrawal. Whether or not treatment in patients who are in longstanding remission can be discontinued is unknown. Key Messages: Available data rely on retrospective data sets and are not conclusive. Some studies indicate that a sustained remission after treatment withdrawal is feasible, whereas other studies have found relapse rates in up to 90% of patients, even in patients with established histological remission. Patients who relapse after drug withdrawal have a high probability for a re-relapse to occur. Life-long maintenance therapy should be strongly considered in these patients, since patients who have multiple relapses are more likely to progress to cirrhosis, liver transplantation and death from liver failure. Conclusion: For a majority of patients, AIH is a lifelong disease requiring permanent treatment. Patients in longstanding clinical remission on monotherapy, with complete normalisation of aminotransferases and IgG could be offered one attempt of drug withdrawal. The risk of disease progression after a single relapse appears low, while a patient's realization that infinite maintenance therapy is mandatory may improve drug adherence.

1.
Waldenstrom J: [Liver, blood proteins and nutritive protein]. Dtsch Z Verdau Stoffwechselkr 1953;9:113-119.
2.
Cowling DC, Mackay IR, Taft LI: Lupoid hepatitis. Lancet 1956;271:1323-1326.
3.
Mackay IR, Weiden S, Hasker J: Autoimmune hepatitis. Ann N Y Acad Sci 1965;124:767-780.
4.
Cook GC, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-185.
5.
Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-737.
6.
Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnićk GL, Elveback IR, et al: Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-833.
7.
Mistilis SP, Blackburn CR: Active chronic hepatitis. Am J Med 1970;48:484-495.
8.
Czaja AJ, Menon KV, Carpenter HA: Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-897.
9.
Montano-Loza AJ, Carpenter HA, Czaja AJ: Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-515.
10.
Johnson PJ, McFarlane IG, Williams R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-963.
11.
de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al: Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147:443-452.e5.
12.
van Gerven NM, de Boer YS, Zwiers A, Verwer BJ, Drenth JP, van Hoek B, et al: HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun 2015;16:247-252.
13.
van Gerven NM, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al: Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014;49:1245-1254.
14.
Gleeson D, Heneghan MA; British Society of Gastroenterology: British society of gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60:1611-1629.
15.
Stern RB, Murray-Lyon IM, Williams R: Controlled trial of corticosteroids and azathioprine in active chronic hepatitis. Gut 1973;14:419.
16.
Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R: Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8:781-784.
17.
Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA: Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-591.
18.
Czaja AJ, Carpenter HA: Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51:968-975.
19.
Bajaj JS, Saeian K, Varma RR, Franco J, Knox JF, Podoll J, et al: Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005;100:1121-1125.
20.
Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ: Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007;133:1779-1786.
21.
Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, et al: Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-1435; quiz 1436.
22.
Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-936.
23.
Biank VF, Sheth MK, Talano J, Margolis D, Simpson P, Kugathasan S, et al: Association of Crohn's disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011;159:808-812.
24.
Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, et al; CESAME Study Group: Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-1423.
25.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al; Cesame Study Group: Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-1628.e1-e5.
26.
Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, et al: Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1324-1329.
27.
Marcén R, Pascual J, Tato AM, Teruel JL, Villafruela JJ, Fernández M, et al: Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003;35:1714-1716.
28.
Silman AJ, Petrie J, Hazleman B, Evans SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-992.
29.
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al; CESAME Study Group: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-1625.
30.
Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Björnsson E, et al: Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388-393.
31.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al; American Association for the Study of Liver Diseases: Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
32.
Montano-Loza AJ, Carpenter HA, Czaja AJ: Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102:1005-1012.
33.
Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-883.
34.
Lüth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP, et al: Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42:926-930.
35.
Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E, et al: Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009;104:2760-2767.
36.
Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, et al; Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID): Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-85.
37.
Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A: Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5-9.
38.
Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A: Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99:1510-1516.
39.
Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R: Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-689.
40.
Czaja AJ, Beaver SJ, Shiels MT: Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987;92:215-219.
41.
Heneghan MA, McFarlane IG: Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13.
42.
van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, et al: Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013;58:141-147.
43.
Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, et al: Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 2015;62:642-646.
44.
Czaja AJ, Wolf AM, Baggenstoss AH: Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80:687-692.
45.
Czaja AJ: Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment Pharmacol Ther 2014;39:1043-1058.
46.
Yokokawa J, Kanno Y, Saito H, Abe K, Takahashi A, Yokokawa H, et al: Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan. Hepatol Res 2011;41:641-646.
47.
Czaja AJ, Ammon HV, Summerskill WH: Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-523.
48.
Czaja AJ, Carpenter HA: Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23:116-123.
49.
Czaja AJ, Davis GL, Ludwig J, Taswell HF: Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-627.
50.
Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, et al: Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24:1197-1205.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.